Evidence map›Paper›PMID 42315818›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Platelet-to-lymphocyte ratio and systemic inflammation response index are the optimal combination for risk stratification in patients with nasopharyngeal carcinoma.

Lin Xu, Biwen Wu, Ruiting Xian, Yun Zhou, Jiajun Li, Zexin Yi, Hanfei Tang, Yonghao Li, Peipei Wang, Yong Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lin Xu *The First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China.
Biwen Wu *Department of Oncology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, People's Republic of China.
Ruiting Xian *Department of Interventional Oncology, Shenzhen Fuyong People's Hospital, Shenzhen, 518103, People's Republic of China.
Yun ZhouDepartment of Oncology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, People's Republic of China.
Jiajun LiDepartment of Oncology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, People's Republic of China.
Zexin YiDepartment of Oncology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, People's Republic of China.
Hanfei TangDepartment of Interventional Medicine, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, People's Republic of China.
Yonghao LiDepartment of Oncology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, People's Republic of China. eyliyonghao@scut.edu.cn.
Peipei WangDepartment of Oncology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, People's Republic of China. eywpp@scut.edu.cn.ORCID http://orcid.org/0000-0001-7201-4928
Yong WuDepartment of Oncology, School of Medicine, The Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, 510180, People's Republic of China. eywuyong@scut.edu.cn.

Funding

National Natural Science Foundation of China No. 82103103
6 · The paper itself

Abstract

backgroundPatients with nasopharyngeal carcinoma (NPC) are often diagnosed at advanced stages or with metastases, and they continue to face significant treatment challenges. Consequently, there is an urgent need to develop novel biomarkers to predict outcomes in these patients. Recently, the prognostic importance of pretreatment immunoinflammatory response in cancer patients has received increasing attention.

methodsThe clinical information of 361 patients with NPC in our clinical center was collected for analysis.

resultsHigh platelet-to-lymphocyte ratio (PLR) and systemic inflammatory response index (SIRI) were associated with poor overall survival (OS) in patients with NPC (P < 0.05). These two indicators collectively formed the optimal combination model for predicting the prognosis of NPC. Notably, a nomogram model that integrated the PLR-SIRI-based risk score, TNM stage, EBV-DNA, gender, and age demonstrated a good ability to predict the 1-, 3-, 5- and 10-year OS rates for NPC patients. Importantly, the novel risk stratification derived from the nomogram model outperformed traditional risk stratification based on TNM stage in predicting the prognosis of NPC patients (P < 0.001).

conclusionsPLR and SIRI collectively form the optimal prognostic model for NPC patients, providing a prognostic risk stratification tool for clinical evaluation.

Indexed as

BiomarkerImmunoinflammatory indexNasopharyngeal carcinomaPrognosisRisk stratification

Identifiers

PMID42315818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.